Position/s

NHMRC Senior Principal Research Fellow and Professor
Clinical Pharmacology

Biography

Professor Mackenzie was awarded a PhD from the University of Sydney (Biochemistry Department, 1976). He held post doctoral positions at the University of Kuopio, Finland (Physiology Department, 1976-1980), National Institutes of Health, Maryland, USA (NICHD, 1980-1987) before returning to Flinders University (Clinical Pharmacology) in 1987 as a NHMRC Research Fellow. He is currently a NHMRC Senior Principal Research Fellow in the Department.

Qualifications

B.SC (hons 1)
PhD

Honours, awards and grants

  • Awarded Fogarty International Fellowship for postdoctoral studies at the National Institutes of Health USA (1980-1983) appointed visiting associate in 1983 and visiting scientist in 1986.
  • Awarded NHMRC Fellowship (1987), SRF (1991), PRF (1994), SPRF (2000).
  • Awarded UICC International Cancer Research Fellowship (1993).
  • Elected ASCEPT visitor to the British Toxicological Society, 2000.
  • Honoured as the 11th Dr Chiravat Sodavongvivad Memorial Lecturer to the Thai Pharmacological Society, Chiangmai, Thailand in 2004.
  • Awarded the Asia/Pacific Scientific Achievement Award for 2006 from the International Society for the Study of Xenobiotics, 2006.
  • Awarded the MICHAEL RAND MEDAL for 2009 by ASCEPT.

Key responsibilities

  • Research only
  • Honours and Postgraduate research supervision

Research expertise

  • Biochemistry and cell biology
  • Pharmacology and pharmaceutical sciences

Research interests

Our defense against the toxic effects of small organic molecules is mediated by families of enzymes found in the internal membranes of cells. Many small organic molecules, such as environmental pollutants, carcinogens and therapeutic drugs, are fat-soluble and will accumulate in the body to toxic levels unless they are modified, usually by the addition of sugar groups. The modified chemical, in the majority of cases, is less toxic and readily removed from the body. We have identified and characterized many of the sugar-transferring enzymes involved in this detoxification process. We are investigating how these enzymes are controlled in the cell and whether there are genetic differences in control processes that may impact on our ability to detoxify drugs and chemicals. This research may provide strategies to help reduce the risk of chemical-induced carcinogenesis and hormone-dependent cancers, such as those of the prostate and breast.

Supervisory interests

  • Drug metabolising enzymes, cytochrome P450 and UDP-glucuronosyltransferase
  • Gene expression
  • MicroRNA-regulated gene expression

RHD research supervision

Current

Principal supervisor : Molecular Pharmacology (3) ;

Associate supervisor : Molecular Pharmacology (2) ;

Publications

  • Mackenzie, P.I., Gardner-Stephen, D.A. and Miners, J.O. (2010). UDP-Glucuronosyltransferases. In Charlene A. McQueen, ed. Comprehensive Toxicology. 2nd ed. United Kingdom: Elsevier, pp. 413-433.
    [10.1016/B978-0-08-046884-6.00420-6]
  • Miners, J.O., Polasek, T.M., Mackenzie, P.I. and Knights, K.M. (2010). The In Vitro Characterization of Inhibitory Drug-Drug Interactions Involving UDP-Glucuronosyltransferase. In K. Sandy Pang, A. David Rodrigues, Raimund M. Peter, ed. Enzyme- and Transporter-Based Drug-Drug Interactions. New York, USA: Springer, pp. 217-236.
    [10.1007/978-1-4419-0840-7_8]
  • Radominska-Pandya, A., Mackenzie, P.I. and Xie, W. (2004). Transciptional Regulation of UDP-Glucuronosyltransferases. In Lawrence H. Lash, ed. DRUG METABOLISM AND TRANSPORT: MOLECULAR METHODS AND MECHANISMS. Totowa, New Jersey: Humana Press, pp. 133-172.
  • Mackenzie, P.I., Rogers, A., Haines, A.Z., Miners, J.O., Gardner-Stephen, D.A. and Meech, R. (2010). Characterization of the Novel UDP Glycosyltransferase 3 Family. In Program and Abstract Book, 18th International Symposium on Microsomes and Drug Oxidations. 18th International Symposium on Microsomes and Drug Oxidations. Beijing, China. May 2010, pp. 73-73.
  • Miners, J.O., Chau, N., Elliot, D.J. and Mackenzie, P.I. (2010). Glucuronidation and Glucosidation are Parallel Metabolic Pathways: Studies with the Model Substrate Morphine. In Program and Abstract Book, 18th International Symposium on Microsomes and Drug Oxidations. 18th International Symposium on Microsomes and Drug Oxidations. Beijing, China. May 2010, pp. 75-75.
  • Mackenzie, P.I., Hu, D.G., Meech, R. and Gardner-Stephen, D.A. (2009). Transcriptional Control of UDP Glucuonosyltransferases. In Jack A Hinson, ed. Drug Metabolism Reviews - Biotransformation and Disposition of Xenobiotics. Informa Healthcare. 3rd Asian Pacific Regional ISSX Meeting. Bangkok, Thailand. May 2009, pp. 16-17.
    [Web Link]
  • Kerdpin, O., Mackenzie, P.I., Bowalgaha Ralalage, K.W., Finel, M. and Miners, J.O. (2009). Roles of N-Terminal Domain Histidine and Proline Residues in the Substrate Selectivities of Human UDP-Glucuronosyltransferase (UGT) 1A1, 1A6, 1A9, 2B7, and 2B10. In Jack A Hinson, ed. Drug Metabolism Reviews - Biotransformation and Disposition of Xenobiotics. Informa Healthcare. 3rd Asian Pacific Regional ISSX Meeting. Bangkok, Thailand. May 2009, pp. 70-71.
    [Web Link]
  • Ishii, Y., Iwamoto, Y., Oizaki, T., Nurrochmad, A., Nishimura, Y., Ikushiro, S., et al. (2009). Cytochrome P450 3A4 Enhances UDP-Glucuronosyltransferase 1A9-catalyzed Glucuronidation of SN-38, an Active Metabolite of Irinotecan. In Jack A Hinson, ed. Drug Metabolism Reviews - Biotransformation and Disposition of Xenobiotics. Informa Healthcare. 3rd Asian Pacific Regional ISSX Meeting. Bangkok, Thailand. May 2009, pp. 69-69.
    [Web Link]
  • Mackenzie, P.I., Meech, R. and Miners, J.O. (2009). Characterization of the UDP Glucosyltransferase 3A Family. In Jack A Hinson, ed. Drug Metabolism Reviews - Biotransformation and Disposition of Xenobiotics. Informa Healthcare. 11th European Regional ISSX Meeting. Portugal, Lisbon. May 2009, pp. 29-29.
    [Web Link]
  • Miners, J.O., Rowland, A., Mackenzie, P.I. and Knights, K.M. (2009). Comparison of the Binding of Drugs to Human Intestinal Fatty Acid Binding Protein and Albumin: Application to In Vitro-In Vivo Extrapolation. In Jack A Hinson, ed. Drug Metabolism Reviews - Biotransformation and Disposition of Xenobiotics. Informa Healthcare. 11th European Regional ISSX Meeting. Portugal, Lisbon. May 2009, pp. 60-61.
    [Web Link]
  • Mackenzie, P.I. and Gardner-Stephen, D.A. (2008). Differential regulation of UDP Glucuronosyltransferase genes by liver enriched transcription factors. In 12th International glucuronidation and UGT workshop. 12th International glucuronidation and UGT workshop. Quebec, Canada. Jul 2008, pp. 35-35.
    [Web Link]
  • Mackenzie, P.I. and Gardner-Stephen, D.A. (2008). Transcriptional regulation of drug metabolising enzymes: the role of liver enriched transcription factors. In Jack A Hinson, ed. Drug Metabolism Reviews. New York: Informa Healthcare. 2nd Asian Pacific Regional ISSX Meeting. Shanghai, China. May 2008, pp. 18-18.
    [10.1080/03602530802110389]
  • Miners, J.O., Rowland, A., Mackenzie, P.I., Uchaipichat, V.N. and Knights, K.M. (2008). In vitro-in vivo extrapolation for glucuronidated drugs. In 12th International glucuronidation and UGt workshop. 12th International glucuronidation and UGt workshop. Quebec, Canada. Jul 2008, pp. 32-32.
    [Web Link]
  • Polasek, T.M., Rowland, A., Elliot, D.J., Knights, K.M., Mackenzie, P.I., Polak, S., et al. (2008). Incorporating inter-individual variability into the prediction of phenytoin clearance from albumin-adjusted in vitro data. In Jack A. Hinson, ed. Drug Metabolism Reviews. Supplement 1 ed. New York, USA: Informa Healthcare. 10th European Regional ISSX meeting. Vienna, Austria. May 2008, pp. 51-51.
  • Gardner-Stephen, D.A., Gillis, J.L., Rogers, A. and Mackenzie, P.I. (2007). Hepatocyte nuclear factor 1 alpha regulates human UDP-glucuronosyltransferase genes via several distinct mechanisms. In C G Sobey and S Smid, ed. 2007 Joint Meeting of ASCEPT and SEAWP-RMP. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 41st Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Adelaide, SA. Dec 2007, pp. 2-97-2-97.
  • Elliot, D.J., Rowland, A., Knights, K.M., Mackenzie, P.I. and Miners, J.O. (2007). Effect of albumin on in vitro lignocaine kinetics - revealing the 'true' contribution of CYP1A2. In C G Sobey, S Smid, ed. 2007 Joint Meeting of ASCEPT and SEAWP-RMP. The Australasion Society of Clinical and Experimental Pharmacologists and Toxicologists. 41st Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Adelaide, SA. Dec 2007, pp. 3-51-3-51.
  • Ishii, Y., Takeda, S., Nurrochmad, A., Iwamoto, Y., Ito, Y., Mackenzie, P.I., et al. (2007). Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: possible involvement of a region located in the J-helix of CYP3A4 in the interaction. In Jack A. Hinson, ed. Drug Metabolism Reviews: Abstracts from the 8th International ISSX meeting. Informa Healthcare. 8th International ISSX meeting. Sendai, Japan. Oct 2007, pp. 301-302.
    [10.1080/03602530701532865]
  • Sallustio, B., Southwood, H., DeGraaf, Y., Mackenzie, P.I., Miners, J.O. and Burcham, P. (2007). Glucuronidation-dependent DNA nicking by carboxylic acid drugs in HEK293 cells expressing human UDP-glucuronosyltransferases. In Jack A. Hinson, ed. Drug metabolism reviews: Abstracts from the 8th international ISSX meeting. Informa Healthcare. 8th International ISSX meeting. Sendai, Japan. Oct 2007, pp. 144-145.
    [10.1080/03602530701532865]
  • Rowland, A., Elliot, D.J., Knights, K.M., Mackenzie, P.I. and Miners, J.O. (2007). Sequestration of long chain unsaturated fatty acids by albumin enhances phenytoin hydroxylation in vitro: implications for clearance prediction. In C G Sobey and S Smid, ed. 2007 Joint meeting of ASCEPT and SEAWP-RMP. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 41st Annual Scientific meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Adelaide, SA. Dec 2007, pp. 1-9-1-9.
  • Rogers, A. and Mackenzie, P.I. (2007). Expression of UDP-Glucuronosyltransferase 1A1 in the MCF7 breast cancer cell line protects against genotoxic and cytotoxic effects of benzo(alpha)pyrene. In C G Sobey and S Smid, ed. 2007 Joint meeting of ASCEPT and SEAWP-RMP. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 41st Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Adelaide, SA. Dec 2007, pp. 3-88-3-88.
  • Miners, J.O., Rowland, A., Uchaipichat, V.N., Elliot, D.J., Knights, K.M. and Mackenzie, P.I. (2007). Unravelling the kinetic anomalies of UDP-glucuronosyltransferases. In Jack A. Hinson, ed. Drug Metabolism Reviews: Abstracts from the 8th International ISSX Meeting. United States: Informa Healthcare. 8th International ISSX Meeting. Sendai, Japan. Oct 2007, pp. 11-11.
    [10.1080/03602530701532865]
  • Lewis, B.C., Mackenzie, P.I. and Miners, J.O. (2007). Identification of the cytochrome P4501A1 (CYP1A1) residues involved in 7-ethoxyresorufin o-deethylation. In C G Sobey and S Smid, ed. 2007 Joint Meeting of ASCEPT and SEAWP-RMP. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 41st Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Adelaide, SA. Dec 2007, pp. 1-6-1-6.
  • Galetin, A., Uchaipichat, V.N., Mackenzie, P.I., Houston, J.B. and Miners, J.O. (2006). Multisite kinetic modelling of interactions between UDP-glucuronosyltransferase 2B7 (UGT2B7) substrates. In Drug Metabolism Review: Abstracts from the 9th European ISSX Meeting. Taylor & Francis: Philadelphia, PA. 9th European ISSX Meeting 2006. Manchester, UK. Jun 2006, pp. 45-46.
  • Gardner-Stephen, D.A., Rogers, A. and Mackenzie, P.I. (2006). Differential regulation of the human UDP-glucuronosyltransferase genes by liver-enriched transcription factors. In Proceedings of the Australian Health and Medical Research Congress 2006. 3rd Australian Health and Medical Research Congress 2006. Melbourne, VIC. Nov 2006, pp. 156-156.
  • Uchaipichat, V.N., Mackenzie, P.I., Houston, J.B., Galetin, A. and Miners, J.O. (2006). Characterisation of interactions between UDP-glucuronosyltransferase 2B7 (UGT2B7) substrates using multisite kinetic modelling [abstract] In Acta Pharmacologica Sinica: XVth World Congress of Pharmacology - Meeting Abstracts. Oxford: Blackwell Publishing. Pharmacology in the 21st Century: 15th World Congress of Pharmacology. Beijing, China. Jun 2006, pp. 218-218.
  • Rowland, A., Gaganis, P., Elliot, D.J., Mackenzie, P.I., Knights, K.M. and Miners, J.O. (2006). Binding of inhibitory fatty acids contributes to the enhancement of UDP-glucuronosyltransferase. In Proceedings of the Australian Health and Medical Research Congress 2006. The 3rd Australian Health & Medical Research Congress (AH&MRC) 2006. Melbourne, VIC. Nov 2006, pp. 402-402.
    [Web Link]
  • Mackenzie, P.I. and Gardner-Stephen, D.A. (2006). Transcriptional regulation of the UDP glucuronosyltransferase gene family. In Drug Metabolism Reviews: Abstracts from the 9th European ISSX Meeting. 9th European ISSX Meeting 2006. Manchester, UK. Jun 2006, pp. 8-8.
    [10.1080/03602530600742037]
  • Mackenzie, P.I. (2006). The UDP glucuronosyltransferase superfamily; our guardian against toxic chemicals. In Drug Metobolism Reviews: Abstracts from the 1st Asia Pacific ISSX Meeting. 1st Asia Pacific ISSX Meeting. Jeju Island, Korea. May 2006.
    [10.1080/03602530600952321]
  • Lewis, B.C., Mackenzie, P.I., Elliot, D.J., Burchell, B., Bhasker, R. and Miners, J.O. (2006). Chimeric UDP-Gucluronosyltransferase (UGT) 2B7 and 2B15 proteins define domains associated with substrate selectivity and autoactivation. In Acta Pharmacologica Sinica: XVth World Congress of Pharmacology - Meeting Abstracts. Oxford: Blackwell Publishing. Pharmacology in the 21st Century: 15th World Congress of Pharmacology. Beijing, China. Jun 2006, pp. 214-214.
  • Udomuksorn, W., Mackenzie, P.I., Lewis, B.C., Elliot, D.J., Yoovathaworn, K. and Miners, J.O. (2006). Coding region mutations in UGT1A1 impair bilirubin and xenobiotic glucuronidation [abstract] In Acta Pharmacologica Sinica: XVth World Congress of Pharmacology - Meeting Abstracts. Oxford: Blackwell Publishing. Pharmacology in the 21st Century: 15th World Congress of Pharmacology. Beijing, China. Jun 2006, pp. 210-210.
  • Lewis, B.C., Mackenzie, P.I. and Miners, J.O. (2005). Homology modeling of cytochrome P4501A1 (CYP1A1) In Proceedings: Joint Meeting of ASCEPT and APSA. Lilydale, VictoriaAnnual Scientific Meeting ASCEPT and APSA. Melbourne, Victoria. Dec 2005.
  • Gardner-Stephen, D.A. and Mackenzie, P.I. (2005). Hepatocyte nuclear transcription factors co-operate to regulate the human UDP glucuronosyltransferase 1A9 gene. In EA Davis, CG Sobey, ed. Joint meeting of ASCEPT and APSA. Lilydale, Victoria: AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS AND TOXICOLOGISTS. Annual Scientific Meeting ASCEPT and APSA. Melbourne. Dec 2005.
  • Bowalgaha Ralalage, K.W., Elliot, D.J., Mackenzie, P.I., Knights, K.M. and Miners, J.O. (2005). Hydroxy-steroids as substrate 'probes' for human UDP glucuronosyltransferases (UGT) In EA Davis, CG Sobey, ed. Joint meeting of ASCEPT and APSA. Lilydale, Australia: AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS AND TOXICOLOGISTS. Annual scientific meeting of ASCEPT and APSA. Melbourne, Australia. Dec 2005.
  • Miners, J.O., Kubota, T., Lewis, B.C., Elliot, D.J. and Mackenzie, P.I. (2005). The identification of substrate binding domains of human UDP-glucuronosyltransferases (UGT) using chimeric proteins. In E. A. Davis and C. G. Sobey, ed. Proceedings, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Lilydale, Vic: Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Annual Scientific Meeting Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Melbourne, Vic.
  • Uchaipichat, V., Mackenzie, P.I., Houston, J., Galetin, A. and Miners, J.O. (2005). Multisite kinetic modelling of interactions between UDP-glucuronosyltransferase 2B7 (UGT2B7) In Proceedings: Joint Meeting of ASCEPT and APSA. Lilydale, VictoriaAnnual Scientific Meeting ASCEPT and APSA. Melbourne, Victoria. Dec 2005.
    [Web Link]
  • Rowland, A., Elliot, D.J., Mackenzie, P.I. and Miners, J.O. (2005). Bovine and human serum albumins enhance UDP glucuronosyltransferase 2B7 (UGT 2B7) activity. In Joint meeting ASCEPT and APSA. Lilydale, Victoria: AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS AND TOXICOLOGISTS. Annual Scientific Meeting ASCEPT and APSA. Melbourne. Dec 2005.
  • Rogers, A. and Mackenzie, P.I. (2005). Regulation of UDP glucuronosyltransferases in CAC02 cells by the caudal related transcription factor, CDX2. In EA Davis, CG Sobey, ed. Joint meeting of ASCEPT and APSA. Lilydale, Australia: AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS AND TOXICOLOGISTS. Annual scientific meeting of ASCEPT and APSA. Melbourne, Australia. Dec 2005.
  • Neilson, J., Gardner-Stephen, D.A. and Mackenzie, P.I. (2005). Transcriptional regulation of the drug and steroid-metabolising UDP glucuronosyltransferase 2B15 gene. In EA Davis, CG Sobey, ed. Joint Meeting of ASCEPT and APSA. Lilydale, Victoria: AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS AND TOXICOLOGISTS. Annual Scientific Meeting of ASCEPT & APSA. Melbourne. Dec 2005.
  • Miners, J.O., Uchaipichat, V., Winner, L., Williamson, J., Elliot, D.J. and Mackenzie, P.I. (2005). The prediction of inhibitory interactions involving glucuronidated drugs from in vitro kinetic data. In JA Hinson, ed. Drug Metabolism Reviews. New York: MARCEL DEKKER INC. 13th North American International Society for the Study of Xc ; Abstracts from 13th NA ISSX/20th JSSX Meeting (Maui, Hawaii, October 2005). Maui Hawaii 23-27 October 2005, pp. 132-132.
  • Gardner-Stephen, D.A. and Mackenzie, P.I. (2004). Hepatocyte nuclear factor 1-alpha regulates the human UPD-glucuronosyltransferase 1A3 gene. In DRUG METABOLISM REVIEWS. 270 MADISON AVE, NEW YORK, USA, NY, 10016: MARCEL DEKKER INC. 7th International ISSX Meeting, pp. 136-136.
  • Gardner-Stephen, D.A. and Mackenzie, P.I. (2004). Regulation of the human UDP-Glucuronosyltransferase 1A3 gene by hepatocyte nuclear factor 1 Alpha. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY. 8th World Conference on Clinical Pharmacology and Therapeutics Incorporating the Annual Scientific Meeting of ASCEPT.
  • Gardner-Stephen, D.A. and Mackenzie, P.I. (2004). Regulation of the human UDP-glucuronosyltransferase 1A3 by hepatocyte nuclear factor 1 alpha. In PROGRAMME AND ABSTRACT. DUNDEE SCOTLAND: UNIVERSITY OF DUNDEE. International Workshop on Glucuronidation, pp. 39-39.
  • Gregory, P. and Mackenzie, P.I. (2004). Regulation of the UPD-glucuronosyltransferase 2B7 gene by the intestine-specific transcription factor Cdx2. In PROGRAMME AND ABSTRACTS. DUNDEE SCOTLAND: UNIVERSITY OF DUNDEE. International Workshop on Glucuronidation, pp. 41-41.
  • Ishii, Y., Futagami, S., , K., Takeda, S., Ikushiro, S., Nagata, K., et al. (2004). Alteration of UDP-glucuronosyltransferase activity in primary cultured rat hepatocytes by RNA interference of cytochrome P450. In PROGRAMME AND ABSTRACTS. DUNDEE SCOTLAND: UNIVERSITY OF DUNDEE. International Workshop on Glucuronidation.
  • Yuan, L., Heydel, J.M., Li, X., Bratton, S., Gardner-Stephen, D.A., Mackenzie, P.I., et al. (2004). Lithocholic acid-mediated FXR suppresses UPD-glucuronosyltransferase 2B7 expression in CACO-2 cells. In DRUG METABOLISM REVIEWS. 270 MADISON AVE, NEW YORK, USA, NY, 10016: MARCEL DEKKER INC. 7th International ISSX Meeting, pp. 316-316.
  • Mackenzie, P.I., Gardner-Stephen, D.A., Gregory, P., Ishii, Y. and Lewinsky, R.H. (2004). Mechanisms of UPD Glucuronosyltransferase Gene Regulation. In PROGRAMME AND ABSTRACTS. DUNDEE SCOTLAND: UNIVERSITY OF DUNDEE. International Workshop on Glucuronidation, pp. 11-11.
  • Mackenzie, P.I., Gardner-Stephen, D.A., Lewinsky, R.H. and Gregory, P. (2004). Liver specific factors and UPD glucuronosyltransferase regulation. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY. 54 UNIVERSITY ST, P O BOX 378, CARLTON, AUSTRALIA, VICTORIA, 3053: BLACKWELL PUBLISHERS INC. 8th World Conference on Clinical Pharmacology & Therapeutics incorporating the Annual Scientific Meeting of ASCEPT, pp. A20-A20.
  • Uchaipichat, V.N., Winner, L., Elliot, D.J., Mackenzie, P.I. and Miners, J.O. (2004). Characterisation of the xenobiotic inhibition selectivity of human UPD-glucuronosyltransferase. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY. 54 UNIVERSITY ST, P O BOX 378, CARLTON, AUSTRALIA, VICTORIA, 3053: BLACKWELL PUBLISHERS INC. 8th World Conference on Clinical Pharmacology & therapeutics incorporating the Annual Scientific Meeting of ASCEPT, pp. A141-A142.
  • Udomuksorn, W., Mackenzie, P.I., Lewis, B.C. and Miners, J.O. (2004). Coding region mutations in human UPD-glucuronosyltransferase 1A1 (UGT1A1) impair bilirubin and xenobiotic glucuronidation. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY. 54 UNIVERSITY ST, P O BOX 378, CARLTON, AUSTRALIA, VICTORIA, 3053: BLACKWELL PUBLISHERS INC. 8th World Conference on Clinical Pharmacology & Therapeutics incorporating the Annual Scientific Meeting of ASCEPT, pp. A141-A141.
  • Yamada, H., Takeda, S., Ishii, Y., Iwanaga, M., Nagata, K., Yamazoe, Y., et al. (2004). Interaction of cytochrome P450 3A4 UPD-glucuronosyltransferase 2B7 (UGT2B7) alters UGT2B7-catalyzed morphine glucuronidation. In PROGRAMME AND ABSTRACTS. DUNDEE SCOTLAND: UNIVERSITY OF DUNDEE. International Workshop on Glucuronidation, pp. 21-21.
  • Mackenzie, P.I. (2004). Determinants of interindividual variability in drug glucuronidation; towards more effective drug therapy. In THAI JOURNAL OF PHARMACOLOGY. BANGKOK: PHARMACOLOGICAL & THERAPEUTIC SOCIETY OF THAILAND. 26th Pharmacological & Therapeutic Society of Thailand, pp. 13-13.
  • Gardner-Stephen, D.A. and Mackenzie, P.I. (2003). A hepatocyte nuclear factor 1 binding element is essntial for expression of the human UDP-glucuronosyltransferase 1A3 gene. (Abstract) In Proceedings of the Australian Society for Medical Research 42nd National Scientific Conference. Adelaide, S.A42nd National Scientific Conference of the Australian Society for Medical Research. Glenelg, SA. Nov 2003, pp. 237.
  • Udomuksorn, W., Mackenzie, P.I., Lewis, B.C. and Miners, J.O. (2003). Influence of coding region mutations (G71R, F83L, P229Q and Y486D) in the human UDP-glucuronosyltransferase 1A1 (UGT1A1) gene on enzyme activity and substrate selectivity. (Abstract) In Davis, EASobey, CG, ed. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Melbourne, VIC, Australia: AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS AND TOXICOLOGISTS. Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Sydney, NSW. Nov 2003, pp. 155.
  • Uchaipichat, V.N., Winner, L., Mackenzie, P.I. and Miners, J.O. (2003). Selectivity of inhibition of human UDP-glucuronosyltransferases by drugs and organic solvents. (Abstract) In Davis, EASobey, CG, ed. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Melbourne, VIC, Australia: AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS AND TOXICOLOGISTS. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Sydney, NSW. Nov 2003, pp. 154.
  • Rogers, C., Mackenzie, P.I. and Miners, J.O. (2003). Influence of amino acids 109 and 396 on the kinetics of xenobiotic phenol glucuronidation by UDP-glucuronosyltransferase 2B4 (Abstract) In Davis, EASobey, CG, ed. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Melbourne, VIC, Australia: AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS AND TOXICOLOGISTS. Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Sydney, NSW. Nov 2003, pp. 148-148.
  • Miners, J.O., Uchaipichat, V.N., Mackenzie, P.I., Galetin, A. and Houston, J.B. (2003). Evidence for atypical glucuronidation kinetics by human UDP-glucuronsyltransferase isoforms. (Abstract) In Davis, EASobey, CG, ed. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Melbourne, VIC, Australia: AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS AND TOXICOLOGISTS. Annual Scientic Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Sydney, NSW. Nov 2003, pp. 99.
  • Gregory, P., Lewinsky, R.H., Gardner-Stephen, D.A. and Mackenzie, P.I. (2003). Regulation of the UDP-glucuronosyltransferase 1A7-10 gene cluster in the gastrointestinal tract (Abstract) In Proceedings of the Australian Society for Medical Research 42nd National Scientific Conference. Adelaide, S.A42nd National Scientific Conference. Glenelg, SA. Nov 2003, pp. 85-85.
  • Gardner-Stephen, D.A., Mackenzie, P.I., Radominska-Pandya, A. and Heydel, J.M. (2002). Co-ordinated induction of proteins involved in drug metabolism and export by the pregnane X receptor (PXR) In The Australian Health and Medical Research Congress. The Australian Health and Medical Research Congress. Melbourne, VIC. Nov 2002, pp. 2110-2110.
  • Gregory, P., Gardner-Stephen, D.A., Lewinsky, R.H., Duncliffe, K.N. and Mackenzie, P.I. (2002). Determinants of the differential expression of the UDP glucuronosyltransferase 1A7-10 gene cluster. In The Australian Health and Medical Research Congress. The Australian Health and Medical Research Congress. Melbourne, VIC. Nov 2002, pp. 2112-2112.
  • Jorgensen, B.R., Smith, P.K., Miners, J.O., Mackenzie, P.I. and McKinnon, R.A. (2002). Towards structural model for UDP glucuronosyltransferase. In The Australian Health and Medical Research Congress. The Australian Health and Medical Research Congress. Melbourne, VIC. Nov 2002, pp. 2113-2113.
  • Lewinsky, R.H. and Mackenzie, P.I. (2002). Characterisation of the human UDP-glucuronosyltransferase 1A10 gene promoter. In The Australian Health & Medical Research Congress. The Australian Health & Medical Research Congress. Melbourne, VIC. Nov 2002, pp. 2115-2115.
  • Mackenzie, P.I., Gregory, P., Gardner-Stephen, D.A., Lewinsky, R.H., Jorgensen, B.R., Nishiyama, T., et al. (2002). Transcriptional regulation of UDP glucuronosyl transferase genes. In The Australian Health and Medical Research Congress. The Australian Health and Medical Research Congress. Melbourne, VIC. Nov 2002, pp. 122-122.
  • Miners, J.O., Chie, E.T., Mackenzie, P.I., Bhasker, R. and Burchell, B. (2002). Identification of a region of UDP-glucuronosyltransferase 2B15 (UGT2B15) involved in substrate selection and binding. In The Australian Health and Medical Reseach Congress. The Australian Health and Medical Reseach Congress. Melbourne, VIC. Nov 2002, pp. 1308-1308.
  • Rogers, C., Mackenzie, P.I., Mckinnon, W., Miners, J.O. and Schober, M. (2002). Leucine-109 alters the substrate selectivity of UDP-glucuronosyltransferase 2B4 (UGT2B4) In The Australian Health and Medical Research Congress. The Australian Health and Medical Research Congress. Melbourne, VIC. Nov 2002, pp. 1309-1309.
  • Miners, J.O. and Mackenzie, P.I. (2001). Structure-function relationships of UDP-glucuronosyltransferases. In Drug Metabolism Reviews. New York: Marcel Dekker. 6th International Meeting of the International Society for the Study of Xenobiotics. Munich, Germany. Oct 2001, pp. 28-28.
  • Stone, A.N., Mackenzie, P.I., Birkett, D.J. and Miners, J.O. (2001). An investigation into morphine glucuronidation. In Drug Metabolism Reviews. New York: Marcel Dekker. 6th International Meeting of the Society of the Study of Xenobiotics. Munich, Germany. Oct 2001, pp. 214-214.
  • Lewinsky, R.H. and Mackenzie, P.I. (2001). Characterization of human UDP Glucuronosytlransferase 1A10. In Drug Metabolism Reviews. New York: Marcel Dekker. 6th International Meeting of the Int Society for the Study of Xenobiotics. Munich, Germany. Oct 2001, pp. 164-164.
  • Mackenzie, P.I. and Gregory, P. (2001). Tissue specific differences in the regulation of UDP glucuronosyltransferases. In Drug Metabolism Reviews. New York: Marcel Dekker. 6th International Meeting of the Int Society for the Study of Xenobiotics. Munich, Germany. Oct 2001, pp. 29-29.
  • Mackenzie, P.I., Gregory, P., Birkett, D.J., Miners, J.O., Lewinsky, R.H., Jorgensen, B.R., et al. (2001). Regulators of UDP glucuronosyltransferase genes in the liver. In WC Hodgson, RE Loiacono, ed. Proc Aust Soc Clin Exp Pharmacol Toxicol. Kew, Victoria, Aust: Australasian Society of Clinical & Experimental Pharmacologists & Toxicologists. Aus Soc Clin Exp Pharmacol Toxicol Annual Scientific Meeting. Dunedin, New Zealand. Dec 2001, pp. 37-37.
  • Miners, J.O., Rowland, A., Uchaipichat, V.N., Elliot, D.J., Knights, K.M., Galetin, A., et al. (2007). In vitro-in vivo extrapolation of drug glucuronidation kinetic parameters: Pitfalls and Promises. In J. Yli-Kauhaluoma, ed. The Taskinen Symposium on Drug Design and Metabolism. Helsinki: Yliopistopaino. The taskinen symposium on drug design and metabolism. University of Helsinki. Aug 2007, pp. 32-35.
  • Hu, D.G., Rogers, A. and Mackenzie, P. (2014). Epirubicin Upregulates UDP Glucuronosyltransferase 2B7 Expression in Liver Cancer Cells via the p53 Pathway. Molecular Pharmacology, 85(6) pp. 887-897.
  • Ishii, Y., Koba, H., Kinoshita, K., Oizaki, T., Iwamoto, Y., Takeda, S., et al. (2014). Alteration of the Function of the UDP-Glucuronosyltransferase 1A Subfamily by Cytochrome P450 3A4: Different Susceptibility for UGT Isoforms and UGT1A1/7 Variants. Drug Metabolism and Disposition, 42(2) pp. 229-238.
    [10.1124/dmd.113.054833]
  • Hu, D.G., Meech, R., Lu, L., McKinnon, R.A. and Mackenzie, P. (2014). Polymorphisms and haplotypes of the UDP-Glucuronosyltransferase 2B7 gene promoter. Drug Metabolism and Disposition, 14(3) pp. 854-862.
  • Hu, D.G., Meech, R., Lu, L., McKinnon, R. and Mackenzie, P. (2014). Polymorphisms and Haplotypes of the UDP-Glucuronosyltransferase 2B7 Gene Promoter. Drug Metabolism and Disposition,
    [10.1124/dmd.113.056630]
  • Chau, N., Elliot, D., Lewis, B., Burns, K., Johnston, M., Mackenzie, P., et al. (2014). Morphine Glucuronidation and Glucosidation Represent Complementary Metabolic Pathways That Are Both Catalyzed by UDP-Glucuronosyltransferase 2B7: Kinetic, Inhibition, and Molecular Modeling Studies. Journal of Pharmacology and Experimental Therapeutics, 349(1) pp. 126-137.
    [10.1124/jpet.113.212258]
  • Hu, D.G., Hickey, T., Irvine, C., Wijayakumara, D., Lu, L., Tilley, W., et al. (2014). Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues. Hormones and Cancer,
    [10.1007/s12672-014-0171-4]
  • Rowland, A., Miners, J.O. and Mackenzie, P.I. (2013). The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification. International Journal of Biochemistry and Cell Biology, 45(6) pp. 1121-1132.
    [10.1016/j.biocel.2013.02.019]
  • Korprasertthaworn, P., Rowland, A., Lewis, B., Mackenzie, P., Yoovathaworn, K. and Miners, J. (2012). Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity. Biochemical Pharmacology, 84(11) pp. 1511-1521.
    [10.1016/j.bcp.2012.08.026] [Scopus]
  • Zhang, H., Patana, A., Mackenzie, P., Ikushiro, S., Goldman, A. and Finel, M. (2012). Human UDP-Glucuronosyltransferase Expression in Insect Cells: Ratio of Active to Inactive Recombinant Proteins and the Effects of a C-Terminal His-Tag on Glucuronidation Kinetics. Drug Metabolism and Disposition, 40(10) pp. 1935-1944.
    [10.1124/dmd.112.046086] [Scopus]
  • Meech, R., Miners, J., Lewis, B. and Mackenzie, P. (2012). The glycosidation of xenobiotics and endogenous compounds: Versatility and redundancy in the UDP glycosyltransferase superfamily. Pharmacology and Therapeutics, 134(2) pp. 200-218.
    [10.1016/j.pharmthera.2012.01.009] [Scopus] [Web Link]
  • Meech, R., Rogers, A., Zhuang, L., Lewis, B., Miners, J. and Mackenzie, P. (2012). Identification of Residues That Confer Sugar Selectivity to UDP-Glycosyltransferase 3A (UGT3A) Enzymes. Journal of Biological Chemistry, 287(29) pp. 24122-24130.
    [10.1074/jbc.M112.343608] [Scopus]
  • Ishii, Y., Iida, N., Mackenzie, P. and Yamada, H. (2012). Inhibition of Morphine Glucuronidation in the Liver Microsomes of Rats and Humans by Monoterpenoid Alcohols. Biological and Pharmaceutical Bulletin, 35(10) pp. 1811-1817.
    [10.1248/bpb.b12-00568] [Scopus]
  • Lewis, B., Mackenzie, P. and Miners, J. (2011). Application of Homology Modeling to Generate CYP1A1 Mutants with Enhanced Activation of the Cancer Chemotherapeutic Prodrug Dacarbazine. Molecular Pharmacology, 80(5) pp. 879-888.
    [10.1124/mol.111.072124] [Scopus] [Web Link]
  • Mackenzie, P.I., Rogers, A., Elliot, D.J., Chau, N., Hulin, J., Miners, J.O., et al. (2011). The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution. Molecular Pharmacology, 79(3) pp. 472-478.
    [10.1124/mol.110.069336] [Scopus]
  • Lewis, B., Mackenzie, P. and Miners, J. (2011). Homodimerization of UDP-glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative dimerization domain by protein homology modeling. Biochemical Pharmacology, 82 pp. 2016-2023.
    [10.1016/j.bcp.2011.09.007] [Scopus] [Web Link]
  • Meech, R. and Mackenzie, P.I. (2010). UGT3A: novel UDP-glycosyltransferases of the UGT superfamily. Drug Metabolism Reviews, 42(1) pp. 45-54.
    [10.3109/03602530903205823] [10.3109/03602530903205823] [Scopus] [Web Link]
  • Miners, J.O., Mackenzie, P.I. and Knights, K.M. (2010). The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metabolism Reviews, 42(1) pp. 196-208.
    [10.3109/03602530903210716] [10.3109/03602530903210716] [Scopus]
  • Mackenzie, P.I., Hu, D.G. and Gardner-Stephen, D.A. (2010). The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors. Drug Metabolism Reviews, 42(1) pp. 99-109.
    [10.3109/03602530903209544] [10.3109/03602530903209544] [Scopus]
  • Ismail, S., Hanapi, N.A., Halim, M.R.A., Uchaipichat, V.N. and Mackenzie, P.I. (2010). Effects of Andrographis paniculata and Orthosiphon stamineus Extracts on the Glucuronidation of 4-Methylumbelliferone in Human UGT Isoforms. Molecules, 15 pp. 3578-3592.
    [10.3390/molecules15053578] [10.3390/molecules15053578] [Scopus]
  • Hu, D.G. and Mackenzie, P.I. (2010). Forkhead Box Protein A1 Regulates UDP-Glucuronosyltransferase 2B15 Gene Transcription in LNCaP Prostate Cancer Cells. Drug Metabolism and Disposition, 38(12) pp. 2105-2109.
    [10.1124/dmd.110.035436] [10.1124/dmd.110.035436] [Scopus]
  • Hu, D.G., Gardner-Stephen, D.A., Severi, G., Gregory, P.A., Treloar, J., Giles, G.G., et al. (2010). A Novel Polymorphism in a Forkhead Box A1 (FOXA1) Binding Site of the Human UDP Glucuronosyltransferase 2B17 Gene Modulates Promoter Activity and is associated with altered levels of circulating Androstane-3{alpha},17{beta}-diol Glucuronide. Molecular Pharmacology, 78(4) pp. 714-722.
    [10.1124/mol.110.065953] [10.1124/mol.110.065953] [Scopus]
  • Hu, D.G. and Mackenzie, P.I. (2009). Estrogen Receptor {alpha}, Fos-Related Antigen-2, and c-Jun Coordinately Regulate Human UDP Glucuronosyltransferase 2B15 and 2B17 Expression in Response to 17b-Estradiol in MCF-7 cells. Molecular Pharmacology, 76(2) pp. 425-439.
    [10.1124/mol.109.057380] [10.1124/mol.109.057380] [Scopus] [Web Link]
  • Kerdpin, O., Mackenzie, P.I., Bowalgaha Ralalage, K.W., Finel, M. and Miners, J.O. (2009). Influence of N-Terminal Domain Histidine and Proline Residues on the Substrate Selectivities of Human UDP-Glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metabolism and Disposition, 37(9) pp. 1948-1955.
    [10.1124/dmd.109.028225] [10.1124/dmd.109.028225] [Scopus] [Web Link]
  • Rowland, A., Knights, K.M., Mackenzie, P.I. and Miners, J.O. (2009). Characterization of the Binding of Drugs to Human Intestinal Fatty Acid Binding Protein (IFABP): Potential Role of IFABP as an Altenative to Albumin for in Vitro-in Vivo Extrapolation of Drug Kinetic Parameters. Drug Metabolism and Disposition, 37(7) pp. 1395-1403.
    [10.1124/dmd.109.027656] [Scopus] [Web Link]
  • Takeda, S., Ishii, Y., Iwanaga, M., Nurrochmad, A., Ito, Y., Mackenzie, P.I., et al. (2009). Interaction of Cytochrome P450 3A4 and UDP-Glucuronosyltransferase 2B7: Evidence for Protein-Protein Association and Possible Involvement of CYP3A4 J-Helix in the Interaction. Molecular Pharmacology, 75(4) pp. 956-964.
    [10.1124/mol.108.052001] [10.1124/mol.108.052001] [Scopus]
  • Sorich, M.J., Smith, P.A., Miners, J.O., Mackenzie, P.I. and McKinnon, R. (2008). Recent advances in the in silico modelling of UDP Glucuronosyltransferase Substrates. Current Drug Metabolism, 9(1) pp. 60-69.
    [10.2174/138920008783331167] [10.2174/138920008783331167] [Scopus]
  • Uchaipichat, V.N., Galetin, A., Houston, J., Mackenzie, P.I., Williams, A. and Miners, J.O. (2008). Kinetic modeling of the interactions between 4-Methylumbelliferone, 1-Naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Molecular Pharmacology, 74(4) pp. 1152-1162.
    [10.1124/mol.108.048645] [10.1124/mol.108.048645] [Scopus]
  • Rowland, A., Elliot, D.J., Knights, K.M., Mackenzie, P.I. and Miners, J.O. (2008). The "Albumin Effect" and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9. Drug Metabolism and Disposition, 36(5) pp. 870-877.
    [10.1124/dmd.107.019885] [10.1124/dmd.107.019885] [Scopus]
  • Mackenzie, P.I., Rogers, A., Gillis, J.L., Jorgensen, B.R., Miners, J.O. and Meech, R. (2008). Identification of UDP Glycosyltransferase 3A1 as a UDP N-Acetylglucosaminyltransferase. Journal of Biological Chemistry, 283(52) pp. 36205-36210.
    [10.1074/jbc.M807961200] [10.1074/jbc.M807961200] [Scopus]
  • Itaaho, K., Mackenzie, P.I., Ikushiro, S., Miners, J.O. and Finel, M. (2008). The configuration of the 17-hydroxy group variably influences the glucuronidation of B-estradiol and epiestradiol by human UDP-Glucuronosyltransferases. Drug Metabolism and Disposition, 36(11) pp. 2307-2315.
    [10.1124/dmd.108.022731] [10.1124/dmd.108.022731] [Scopus]
  • Gardner-Stephen, D.A. and Mackenzie, P.I. (2008). Liver-enriched transcription factors and their role in regulating UDP glucuronosyltransferase gene expression. Current Drug Metabolism, 9(5) pp. 439-452.
    [10.2174/138920008784746409] [10.2174/138920008784746409] [Scopus]
  • Rowland, A., Knights, K.M., Mackenzie, P.I. and Miners, J.O. (2008). The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metabolism and Disposition, 36(6) pp. 1056-1062.
    [10.1124/dmd.108.021105] [10.1124/dmd.108.021105] [Scopus]
  • Bowalgaha, K., Elliot, D.J., Mackenzie, P.I., Knights, K.M. and Miners, J.O. (2007). The glucuronidation of delta4-3-keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metabolism and Disposition, 35(3) pp. 363-370.
    [10.1124/dmd.106.013052] [10.1124/dmd.106.013052] [Scopus]
  • Gardner-Stephen, D.A. and Mackenzie, P.I. (2007). Hepatocyte nuclear factor1 transcription factors are essential for the UDP-glucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4alpha. Pharmacogenetics and Genomics, 17(1) pp. 25-36.
    [10.1097/FPC.0b013e32801112b5] [10.1097/FPC.0b013e32801112b5] [Scopus]
  • Gardner-Stephen, D.A. and Mackenzie, P.I. (2007). Isolation of the UDP-glucuronosyltransferase 1A3 and 1A4 proximal promoters and characterization of their dependence on the transcription factor hepatocyte nuclear factor 1 alpha. Drug Metabolism and Disposition, 35(1) pp. 116-120.
    [10.1124/dmd.106.012203] [10.1124/dmd.106.012203] [Scopus]
  • Ishii, Y., Iwanaga, M., Nishimura, Y., Takeda, S., Ikushiro, S., Nagata, K., et al. (2007). Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-Glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex. Drug Metabolism and Pharmacokinetics, 22(5) pp. 367-376.
    [10.2133/dmpk.22.367] [Scopus] [Web Link]
  • Kubota, T., Lewis, B.C., Elliot, D.J., Mackenzie, P.I. and Miners, J.O. (2007). Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. Molecular Pharmacology, 72(4) pp. 1054-1062.
    [10.1124/mol.107.037952] [10.1124/mol.107.037952] [Scopus]
  • Kurkela, M., Patana, A., Mackenzie, P.I., Court, M.H., Tate, C.G., Hirvonen, J., et al. (2007). Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6. Pharmacogenetics and Genomics, 17(2) pp. 115-126.
    [10.1097/FPC.0b013e328011b598] [10.1097/fpc.0b013e328011b598] [Scopus]
  • Lewis, B.C., Mackenzie, P.I. and Miners, J.O. (2007). Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis. Archives of Biochemistry and Biophysics, 468(1) pp. 58-69.
    [10.1016/j.abb.2007.09.014] [10.1016/j.abb.2007.09.014] [Scopus]
  • Lewis, B.C., Mackenzie, P.I., Elliot, D.J., Burchell, B., Bhasker, R. and Miners, J.O. (2007). Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochemical Pharmacology, 73(9) pp. 1463-1473.
    [10.1016/j.bcp.2006.12.021] [10.1016/j.bcp.2006.12.021] [Scopus]
  • Nishimura, Y., Maeda, S., Ikushiro, S., Mackenzie, P.I., Ishii, Y. and Yamada, H. (2007). Inhibitory effects of adenine nucleotides and related substances on UDP-glucuronosyltransferase: structure-effect relationships and evidence for an allosteric mechanism. Biochimica et Biophysica Acta-General Subjects, 1770(11) pp. 1557-1566.
    [10.1016/j.bbagen.2007.07.011] [10.1016/j.bbagen.2007.07.011] [Scopus]
  • Rowland, A., Gaganis, P., Elliot, D.J., Mackenzie, P.I., Knights, K.M. and Miners, J.O. (2007). Binding of inhibitory fatty acids is responsible for the enhancement of UDP-Glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. Journal of Pharmacology and Experimental Therapeutics, 321(1) pp. 137-147.
    [10.1124/jpet.106.118216] [10.1124/jpet.106.118216] [Scopus]
  • Southwood, H., DeGraaf, Y., Mackenzie, P.I., Miners, J.O., Burcham, P. and Sallustio, B. (2007). Carboxylic Acid Drug-Induced DNA Nicking in HEK293 Cells Expressing Human UDP-Glucuronosyltransferases: Role of Acyl Glucuronide Metabolites and Glycation Pathways. Chemical Research in Toxicology, 20(10) pp. 1520-1527.
    [10.1021/tx700188x] [10.1021/tx700188x] [Scopus]
  • Udomuksorn, W., Elliot, D.J., Lewis, B.C., Mackenzie, P.I., Yoovathaworn, K. and Miners, J.O. (2007). Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenetics and Genomics, 17(12) pp. 1017-1029.
    [10.1097/FPC.0b013e328256b1b6] [10.1097/FPC.0b013e328256b1b6] [Scopus]
  • Takeda, S., Kitajima, Y., Ishii, Y., Nishimura, Y., Mackenzie, P.I., Oguri, K., et al. (2006). Inhibition of UDP-glucuronosyltransferase 2B7-catalyzed morphine glucuronidation by Ketoconazole: Dual mechanisms involving a novel non-competitive mode. Drug Metabolism and Disposition, 34(8) pp. 1277-1282.
    [10.1124/dmd.106.009738] [10.1124/dmd.106.009738] [Scopus]
  • Rowland, A., Elliot, D.J., Williams, A., Mackenzie, P.I., Dickinson, R.G. and Miners, J.O. (2006). In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metabolism and Disposition, 34(6) pp. 1055-1062.
    [10.1124/dmd.106.009340] [10.1124/dmd.106.009340] [Scopus]
  • Okamura, K., Ishii, Y., Ikushiro, S., Mackenzie, P.I. and Yamada, H. (2006). Fatty acyl-CoA as an endogenous activator of UDP-glucuronosyltransferases. Biochemical and Biophysical Research Communications, 345(4) pp. 1649-1656.
    [10.1016/j.bbrc.2006.05.089] [10.1016/j.bbrc.2006.05.089] [Scopus]
  • Miners, J.O., Knights, K.M., Houston, J.B. and Mackenzie, P.I. (2006). In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises. Biochemical Pharmacology, 71(11) pp. 1531-1539.
    [10.1016/j.bcp.2005.12.019] [10.1016/j.bcp.2005.12.019] [Scopus]
  • Uchaipichat, V.N., Winner, L., Mackenzie, P.I., Elliot, D.J., Williams, A. and Miners, J.O. (2006). Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. British Journal of Clinical Pharmacology, 61(4) pp. 427-439.
    [10.1111/j.1365-2125.2006.02588.x] [10.1111/j.1365-2125.2006.02588.x] [Scopus]
  • Gregory, P., Gardner-Stephen, D.A., Rogers, A., Michael, M.Z. and Mackenzie, P.I. (2006). The caudal-related homeodomain protein Cdx2 and hepatocyte nuclear factor 1-alpha cooperatively regulate the UDP-glucuronosyltransferase 2B7 gene promotor. Pharmacogenetics and Genomics, 16(7) pp. 527-536.
    [10.1097/01.fpc.0000215068.06471.35] [10.1097/01.fpc.0000215068.06471.35] [Scopus]
  • Boyd, M.A., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P.I., Uchaipichat, V.N., Stek, M., et al. (2006). Relationship between hyperbilirubinaemia and UDP-glucoronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenetics and Genomics, 16(5) pp. 321-329.
    [10.1097/01.fpc.0000197465.14340.d4] [10.1097/01.fpc.0000197465.14340.d4] [Scopus]
  • Uchaipichat, V.N., Mackenzie, P.I., Elliot, D.J. and Miners, J.O. (2006). Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) 'probes' for human UDP-glucuronosyltransferases. Drug Metabolism and Disposition, 34(3) pp. 449-456.
    [10.1124/dmd.105.007369] [10.1124/dmd.105.007369] [Scopus]
  • Kerdpin, O., Elliot, D.J., Mackenzie, P.I. and Miners, J.O. (2006). Sulfinpyrazone C-Glucuronidation Is Catalyzed Selectively by Human UDP-Glucuronosyltransferase 1A9. Drug Metabolism and Disposition, 34(12) pp. 1950-1953.
    [10.1124/dmd.106.012385] [10.1124/dmd.106.012385] [Scopus]
  • Mackenzie, P.I., Gregory, P.A., Lewinsky, R., Yasmin, S.N., Height, T., MacKinnon, R.A., et al. (2005). Polymorphic variations in the expression of the chemical detoxifying UDP glucuronosytransferases. Toxicology and Applied Pharmacology, 207(Issue 2 SUPPL.) pp. S77-S83.
    [10.1016/j.taap.2004.12.026] [10.1016/j.taap.2004.12.026] [Scopus]
  • Mackenzie, P.I., Bock, K.W., Burchell, B., Guillemette, C., Iyanagi, T., Miners, J.O., et al. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenetics and Genomics, 15(10) pp. 677-685.
    [Scopus]
  • Mackenzie, P., Gregory, P., Lewinsky, R., Yasmin, S., Height, T., McKinnon, R.A., et al. (2005). Polymorphic variations in the expression of chemical detoxifying UDP glucuronosyltransferases. Toxicology and Applied Pharmacology, 77(Suppl 2) pp. 77-83.
  • Lewinsky, R., Smith, P. and Mackenzie, P.I. (2005). Glucuronidation of bioflavonoids by human UGT1A10: structure-function relationships. Xenobiotica, 35(2) pp. 117-129.
    [10.1080/00498250400028189] [10.1080/00498250400028189] [Scopus]
  • Gardner-Stephen, D.A., Gregory, P. and Mackenzie, P.I. (2005). Identification and characterization of functional hepatocyte nuclear factor 1-binding sites in UDP-glucuronosyltransferase genes. Methods in Enzymology, 400(2) pp. 22-46.
    [10.1016/S0076-6879(05)00002-9] [10.1016/S0076-6879(05)00002-9] [Scopus]
  • Finel, M., Li, X., Gardner-Stephen, D.A., Bratton, S., Mackenzie, P.I. and Radominska-Pandya, A. (2005). Human UDP-glucuronosyltransferase 1A5: indentification, expression and activity. Journal of Pharmacology and Experimental Therapeutics, 315(3) pp. 1143-1149.
    [10.1124/jpet.105.091900] [10.1124/jpet.105.091900] [Scopus]
  • Bowalgaha Ralalage, K.W., Elliot, D.J., Mackenzie, P.I., Knights, K.M., Swedmark, S. and Miners, J.O. (2005). S-Naproxen and desmethylnaproxen glucuronidation by human liver miscrosomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. British Journal of Clinical Pharmacology, 60(4) pp. 423-433.
    [10.1111/j.1365-2125.2005.02446.x] [10.1111/j.1365-2125.2005.02446.x] [Scopus]
  • Takeda, S., Ishii, Y., Iwanaga, M., Mackenzie, P.I., Nagata, K., Yamazoe, Y., et al. (2005). Modulation of UDP-glucuronosyltransferase function by cytochrome P450: Evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Molecular Pharmacology, 67(3) pp. 665-672.
    [10.1124/mol.104.007641] [10.1124/mol.104.007641] [Scopus]
  • Takeda, S., Ishii, Y., Mackenzie, P.I., Nagata, K., Yamazoe, Y., Oguri, K., et al. (2005). Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: Differential effects of CYP1A2, CYP2C9 and CYP3A4. Biological and Pharmaceutical Bulletin, 28(10) pp. 2026-2027.
    [10.1248/bpb.28.2026] [10.1248/bpb.28.2026] [Scopus]
  • Gardner-Stephen, D.A., Heydel, J.M., Goyal, A., Lu, Y., Xie, W., Lindblom, T., et al. (2004). Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metabolism and Disposition, 32(3) pp. 340-347.
    [10.1124/dmd.32.3.340] [10.1124/dmd.32.3.340] [Scopus]
  • Gregory, P., Lewinsky, R.H., Gardner-Stephen, D.A. and Mackenzie, P.I. (2004). Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9 and 1A10 genes by hepatocyte nuclear factor 1-alpha and the caudal-related homeodomain protein 2. Molecular Pharmacology, 65(4) pp. 953-963.
    [10.1124/mol.65.4.953] [10.1124/mol.65.4.953] [Scopus]
  • Gregory, P., Lewinsky, R.H., Gardner-Stephen, D.A. and Mackenzie, P.I. (2004). Regulation of UDP-glucuronosyltransferases in the gastrointestinal tract. Toxicology and Applied Pharmacology, 199(3) pp. 354-363.
    [10.1016/j.taap.2004.01.008] [10.1016/j.taap.2004.01.008] [Scopus]
  • Miners, J.O., Smith, P.A., Sorich, M.J., McKinnon, R.A. and Mackenzie, P.I. (2004). Predicating Human Drug Glucuronidation Parameters: Application of In Vitro and InSilico Modeling Approaches. Annual Review of Pharmacology and Toxicology, 44 pp. 1-25.
    [10.1146/annurev.pharmtox.44.101802.121546] [10.1146/annurev.pharmtox.44.101802.121546] [Scopus]
  • Oguri, T., Takahashi, T., Miyazaki, M., Isobe, T., Kohno, N., Mackenzie, P.I., et al. (2004). UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Research, 24(5 A) pp. 2893-2896.
    [Scopus] [Web Link]
  • Uchaipichat, V.N., Mackenzie, P.I., Guo, X.H., Gardner-Stephen, D.A., Galetin, A., Houston, J.B., et al. (2004). Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumberlliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metabolism and Disposition, 32(4) pp. 413-423.
    [10.1124/dmd.32.4.413] [10.1124/dmd.32.4.413] [Scopus]
  • Wells, P.G., Mackenzie, P.I., Chowdhury, J.R., Guillemette, C., Gregory, P., Ishii, Y., et al. (2004). Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metabolism and Disposition, 32(3) pp. 281-290.
    [10.1124/dmd.32.3.281] [10.1124/dmd.32.3.281] [Scopus]
  • Gregory, P., Gardner-Stephen, D.A., Lewinsky, R.H., Duncliffe, K.N. and Mackenzie, P.I. (2003). Cloning and characterization of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters: differential regulation through an intitiator-like region. Journal of Biological Chemistry, 278(38) pp. 36107-36114.
    [10.1074/jbc.M305565200] [10.1074/jbc.M305565200] [Scopus]
  • Stone, A.N., Mackenzie, P.I., Galetin, A., Houston, J.B. and Miners, J.O. (2003). Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltranferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metabolism and Disposition, 31(9) pp. 1086-1089.
    [10.1124/dmd.31.9.1086] [10.1124/dmd.31.9.1086] [Scopus]
  • Mackenzie, P.I., Little, J.M. and Radominska-Pandya, A. (2003). Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7. Biochemical Pharmacology, 65(3) pp. 417-421.
    [10.1016/S0006-2952(02)01522-8] [10.1016/S0006-2952(02)01522-8] [Scopus]
  • Mackenzie, P.I., Gregory, P., Gardner-Stephen, D.A., Lewinsky, R.H., Jorgensen, B.R., Nishiyama, T., et al. (2003). Regulation of UDP glucuronosyltransferase genes. Current Drug Metabolism, 4(3) pp. 249-257.
    [10.2174/1389200033489442] [10.2174/1389200033489442] [Scopus]
  • Gregory, P. and Mackenzie, P.I. (2002). The homeodomain Pbx2-Prep1 complex modulates hepatocyte nuclear factor 1 alpha-mediated activation of the UDP-Glucuronosyltransferase 2B17 gene. Molecular Pharmacology, 62(1) pp. 154-161.
    [10.1124/mol.62.1.154] [10.1124/mol.62.1.154] [Scopus]
  • Tukey, R.H., Strassburg, C.P. and Mackenzie, P.I. (2002). Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Molecular Pharmacology, 62(3) pp. 446-450.
    [10.1124/mol.62.3.446] [10.1124/mol.62.3.446] [Scopus]
  • Miners, J.O., Mackenzie, P.I. and McKinnon, R.A. (2002). Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology, 181-182 pp. 453-456.
    [10.1016/S0300-483X(02)00449-3] [10.1016/S0300-483X(02)00449-3] [Scopus]
  • Court, M.H., Duan, S.X., Von Moltke, L.L., Greenblatt, D.J., Patten, C.J., Miners, J.O., et al. (2001). Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. Journal of Pharmacology and Experimental Therapeutics, 299(3) pp. 998-1006.
  • Mackenzie, P., Miners, J. and McKinnon, R.A. (2000). Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clinical Chemistry and Laboratory Medicine, 38(9) pp. 889-892.
  • Mackenzie, P.I., Hu, D.G. and Gardner-Stephen, D.A. (2010). The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors. Drug Metabolism Reviews, 42(1) pp. 99-109.
    [10.3109/03602530903209544] [10.3109/03602530903209544] [Scopus]
  • Hu, D.G., Gardner-Stephen, D.A., Severi, G., Gregory, P.A., Treloar, J., Giles, G.G., et al. (2010). A Novel Polymorphism in a Forkhead Box A1 (FOXA1) Binding Site of the Human UDP Glucuronosyltransferase 2B17 Gene Modulates Promoter Activity and is associated with altered levels of circulating Androstane-3{alpha},17{beta}-diol Glucuronide. Molecular Pharmacology, 78(4) pp. 714-722.
    [10.1124/mol.110.065953] [10.1124/mol.110.065953] [Scopus]
  • Hu, D.G. and Mackenzie, P.I. (2009). Estrogen Receptor {alpha}, Fos-Related Antigen-2, and c-Jun Coordinately Regulate Human UDP Glucuronosyltransferase 2B15 and 2B17 Expression in Response to 17b-Estradiol in MCF-7 cells. Molecular Pharmacology, 76(2) pp. 425-439.
    [10.1124/mol.109.057380] [10.1124/mol.109.057380] [Scopus] [Web Link]
  • Gardner-Stephen, D.A. and Mackenzie, P.I. (2008). Liver-enriched transcription factors and their role in regulating UDP glucuronosyltransferase gene expression. Current Drug Metabolism, 9(5) pp. 439-452.
    [10.2174/138920008784746409] [10.2174/138920008784746409] [Scopus]
  • Mackenzie, P.I., Rogers, A., Gillis, J.L., Jorgensen, B.R., Miners, J.O. and Meech, R. (2008). Identification of UDP Glycosyltransferase 3A1 as a UDP N-Acetylglucosaminyltransferase. Journal of Biological Chemistry, 283(52) pp. 36205-36210.
    [10.1074/jbc.M807961200] [10.1074/jbc.M807961200] [Scopus]
  • Gardner-Stephen, D.A. and Mackenzie, P.I. (2007). Hepatocyte nuclear factor1 transcription factors are essential for the UDP-glucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4alpha. Pharmacogenetics and Genomics, 17(1) pp. 25-36.
    [10.1097/FPC.0b013e32801112b5] [10.1097/FPC.0b013e32801112b5] [Scopus]
  • Mackenzie, P.I., Bock, K.W., Burchell, B., Guillemette, C., Iyanagi, T., Miners, J.O., et al. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenetics and Genomics, 15(10) pp. 677-685.
    [Scopus]
  • Gregory, P., Lewinsky, R.H., Gardner-Stephen, D.A. and Mackenzie, P.I. (2004). Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9 and 1A10 genes by hepatocyte nuclear factor 1-alpha and the caudal-related homeodomain protein 2. Molecular Pharmacology, 65(4) pp. 953-963.
    [10.1124/mol.65.4.953] [10.1124/mol.65.4.953] [Scopus]
  • Gregory, P., Gardner-Stephen, D.A., Lewinsky, R.H., Duncliffe, K.N. and Mackenzie, P.I. (2003). Cloning and characterization of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters: differential regulation through an intitiator-like region. Journal of Biological Chemistry, 278(38) pp. 36107-36114.
    [10.1074/jbc.M305565200] [10.1074/jbc.M305565200] [Scopus]
  • Mackenzie, P.I., Gardner-Stephen, D.A. and Miners, J.O. (2010). UDP-Glucuronosyltransferases. In Charlene A. McQueen, ed. Comprehensive Toxicology. 2nd ed. United Kingdom: Elsevier, pp. 413-433.
    [10.1016/B978-0-08-046884-6.00420-6]

Professional and community engagement

  • Elected member of the American Society of Biochemistry and Molecular Biology in 1987-
  • Elected member of the American Association for the Study of Liver Diseases in 1988-.
  • Fellow of the International Union Against Cancer (UICC) 1995-
  • Councillor of the International Society for the Study of Xenobiotics (ISSX) 1994-1997, 2004-2007
  • Chair of Regional Scientific Affairs Committee (ISSX-Pacific Region) 1993-1997
  • Member of ISSX International Scientific Affairs Committee 1993-1997, Chair, 2008-
  • Appointed to the UDP Glycosyltransferase Nomenclature Committee of the International Union of Biochemistry and Molecular Biology and JUPAC-IUBMB Joint Commission on Biochemical Nomenclature. 1995-
  • Appointed UGT specialist advisor to the HUGO Genome Nomenclature Committee. 2005-

Contact

Add to address book
Phone: +61 8 82045394
Email:
Location: School of Medicine (6D:310.1)
Postal address: GPO Box 2100, Adelaide 5001, South Australia
MACO login

inspiring achievement